GSK Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 21.05
- PEG ratio
- 105.20
- P/B
- 4.39
- P/S (TTM)
- 3.12
- EV/EBITDA
- 9.59
Profitability & growth
- ROE (TTM)
- 33.4%
- Operating margin
- 30.9%
- Revenue growth YoY
- 5.3%
- Dividend yield
- 3.5%
- Beta
- 0.30
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About GlaxoSmithKline PLC ADR
Company profileGlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 79 NEW OXFORD STREET, LONDON, UNITED KINGDOM
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
